Search results for "model."

showing 10 items of 23664 documents

Prognostic impact and implications of extra-capsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis.

2015

The extranodal extension (ENE) of nodal metastasis (i.e. the extension of tumor cells through the nodal capsule into the perinodal adipose tissue) has recently emerged as an important prognostic factor in different types of malignancies. However, the tumor-node-metastasis (TNM) staging system for colorectal cancer does not consider it as a prognostic parameter. Therefore, we conducted a systematic review and meta-analysis to determine the prognostic role of ENE in patients with lymph node-positive colorectal cancer.Two independent authors searched PubMed and SCOPUS until 7 January 2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects wit…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerExtra-capsular extensionColon cancer; ENE; Extra-capsular extension; Extra-nodal extension; Lymph node metastasis; Rectal cancer03 medical and health sciences0302 clinical medicinecolon cancer; extracapsular extension; extranodal extension; lymph node metastasis; rectal cancerInternal medicineHumansMedicineextracapsular extensionRectal cancerProspective cohort studyLymph nodeProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelHazard ratioCancerextranodal extensionHematologyPrognosismedicine.diseaseColon cancerTreatment Outcome030104 developmental biologymedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisMeta-analysisENEextranodal extension extracapsular extension lymph node metastasis colon cancer rectal cancerRegression AnalysisT-stageExtra-nodal extensionLymph NodesNeoplasm Recurrence LocalColorectal Neoplasmsbusiness
researchProduct

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy

2018

ABSTRACT The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe’s largest meeting series of its kind, took place in Mainz, Germany from 15–17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto “Pushing Frontiers in Cancer Immunotherapy”. This meeting report is a summary of some of the CIMT 2018 highlights.

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicineNeoplasmsmedicineTumor MicroenvironmentImmunology and AllergyAnimalsHumansPersonalized therapytumor vaccinationPharmacologypersonalized therapyTumor microenvironmentcancer immunotherapybusiness.industryVaccinationCIMTcellular therapyCongresses as TopicXenograft Model Antitumor AssaysDisease Models Animal030104 developmental biologycheckpoint blockadeDrug Therapy CombinationImmunotherapybusinessHuman Vaccines & Immunotherapeutics
researchProduct

The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives

2021

Immuno-oncology (IO) focuses on the ability of the immune system to detect and eliminate cancer cells. Since the approval of the first immune checkpoint inhibitor, immunotherapies have become a major player in oncology treatment and, in 2021, represented the highest number of approved drugs in the field. In spite of this, there is still a fraction of patients that do not respond to these therapies and develop resistance mechanisms. In this sense, mathematical models offer an opportunity to identify predictive biomarkers, optimal dosing schedules and rational combinations to maximize clinical response. This work aims to outline the main therapeutic targets in IO and to provide a description …

0301 basic medicineOncologymedicine.medical_specialtyComputer scienceImmune checkpoint inhibitorsPharmaceutical ScienceCancer immunityReview03 medical and health sciences0302 clinical medicinePharmacy and materia medicaDosing schedulesInternal medicinemedicineTumor growthimmuno-oncologyPK/PD modelsPredictive biomarkertop-down approachMathematical modelPK/PDmathematical modelingRS1-441030104 developmental biologybottom-up approach030220 oncology & carcinogenesisSpitemiddle-out approachPharmaceutics
researchProduct

Imaging biomarkers of behavioral impairments: A pilot micro-positron emission tomographic study in a rat electrical post-status epilepticus model.

2018

Objective In patients with epilepsy, psychiatric comorbidities can significantly affect the disease course and quality of life. Detecting and recognizing these comorbidities is central in determining an optimal treatment plan. One promising tool in detecting biomarkers for psychiatric comorbidities in epilepsy is positron emission tomography (PET). Methods Results Behavioral and biochemical variables were cross-correlated with the results from two mu PET scans using the tracers [F-18]fluoro-2-deoxy-D-glucose ([F-18]FDG) and 2 '-methoxyphenyl-(N-2 '-pyridinyl)-p-F-18-fluoro-benzamidoethylpiperazine ([F-18]MPPF) to explore potential biomarkers for neurobehavioral comorbidities in an electrica…

0301 basic medicineOncologymedicine.medical_specialtyImaging biomarkerStatus epilepticusHippocampal formationAnxietyHippocampusPositron emission tomographicNesting BehaviorRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compoundEpilepsySeverity assessment0302 clinical medicineStatus EpilepticusFluorodeoxyglucose F18Internal medicinepsychiatric comorbiditieMedicineAnimalsSocial BehaviorElectroshockmedicine.diagnostic_testbusiness.industryanimal modelmedicine.diseaseElectrodes ImplantedRats030104 developmental biologyNeurologychemistryPositron emission tomographyPositron-Emission TomographyepilepsyFemale[18F]MPPFNeurology (clinical)[18F]FDGMPPFmedicine.symptomRadiopharmaceuticalsbusiness030217 neurology & neurosurgeryBiomarkersEpilepsia
researchProduct

2019

Background Body fat and/or muscle composition influences prognosis in several cancer types. For advanced gastric and gastroesophageal junction cancer, we investigated which body composition parameters carry prognostic information beyond well-established clinical parameters using robust model selection strategy such that parameters identified can be expected to generalize and to be reproducible beyond our particular data set. Then we modelled how differences in these parameters translate into survival outcomes. Methods Fat and muscle parameters were measured on baseline computed tomography scans in 761 patients with advanced gastric or gastroesophageal junction cancer from the phase III EXPA…

0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisProportional hazards modelbusiness.industryModel selectionCancermedicine.diseaseCorrelation03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisPhysiology (medical)SarcopeniaInternal medicineCohortmedicineOrthopedics and Sports MedicinebusinessSurvival analysisJournal of Cachexia, Sarcopenia and Muscle
researchProduct

Imaging correlates of behavioral impairments: An experimental PET study in the rat pilocarpine epilepsy model

2018

Abstract Psychiatric comorbidities are prevalent in patients with epilepsy and greatly contribute to the overall burden of disease. The availability of reliable biomarkers to diagnose epilepsy-associated comorbidities would allow for effective treatment and improved disease management. Due to their non-invasive nature, molecular imaging techniques such as positron emission tomography (PET) are ideal tools to measure pathologic changes. In the current study we investigated the potential of [18F]fluoro-2-deoxy- d -glucose ([18F]FDG) and 2′-methoxyphenyl-(N-2′-pyridinyl)-p-18F-fluoro-benzamidoethylpiperazine ([18F]MPPF) as imaging correlates of neurobehavioral comorbidities in the pilocarpine …

0301 basic medicineOncologymedicine.medical_specialtyNeurologyEpileptogenesislcsh:RC321-571Rats Sprague-Dawley03 medical and health sciencesEpilepsychemistry.chemical_compound0302 clinical medicineNeurotrophic factorsInternal medicineMedicineAnimalsInterpersonal RelationsAnimal modellcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBehaviorEpilepsymedicine.diagnostic_testbusiness.industryMental DisordersPilocarpinemedicine.diseaseRatsDisease Models Animal030104 developmental biologyBDNFPETchemistryNeurologyPositron emission tomographyPilocarpinePositron-Emission TomographyReceptor Serotonin 5-HT1ABiomarker (medicine)Female[18F]MPPFMPPF[18F]FDGbusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value

2017

[EN] Background: The average five-year survival for non-small cell lung cancer (NSCLC) patients is approximately 15%. Emerging evidence indicates that microRNAs (miRNAs) constitute a new class of gene regulators in humans that may play an important role in tumorigenesis. Hence, there is growing interest in studying their role as possible new biomarkers whose expression is aberrant in cancer. Therefore, in this study we identified dysregulated miRNAs by next generation sequencing (NGS) and analyzed their prognostic value. Methods: Sequencing by oligo ligation detection technology was used to identify dysregulated miRNAs in a training cohort comprising paired tumor/normal tissue samples (N = …

0301 basic medicineOncologymedicine.medical_specialtyPathologyBIOLOGIA CELULARNSCLCDNA sequencing03 medical and health sciences0302 clinical medicineInternal medicineMedicineLung cancerValenciaSurvival analysisbiologybusiness.industryProportional hazards modelProfilingExperimental validationbiology.organism_classificationmedicine.diseasePrognosismicroRNAsMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisNGSNon small cellPersonalized medicineprognosisprofilingbusinessResearch Paper
researchProduct

Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence…

2021

The introduction of checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC) treatment landscape, resulted in improvements in overall survival (OS) in metastatic patients. Brain metastases (BMs) are a specific metastatic site of interest representing a predictive factor of poor prognosis. Patients with BMs were usually excluded from prospective clinical trials in the past. Despite recent evidence suggest the efficacy and safety of ICIs, the BMs treatment remains a challenge; the immunotherapy responsiveness seems to be multifactorial and dependent on several factors, such as the genetic intratumor heterogeneity and the immunosuppressive role of the brain tumor microenvironment. This revie…

0301 basic medicineOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaImmune checkpoint inhibitorsmedicine.medical_treatmentImmune-checkpoint inhibitorsBrain tumorEpigenetic remodeling03 medical and health sciences0302 clinical medicineImmune systemRenal cell carcinomaInternal medicineTumor MicroenvironmentHumansMedicineProspective StudiesEpigeneticsCarcinoma Renal CellImmune Checkpoint InhibitorsBrain Neoplasmsbusiness.industrySettore MED/37 - NeuroradiologiaCancerBrain metastasesHematologyImmunotherapymedicine.diseaseKidney NeoplasmsRenal cell carcinomaClinical trialRenal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessBrain tumor microenvironmentNeuroradiological response evaluationCritical Reviews in Oncology/Hematology
researchProduct

Prognostic Significance of Focal Adhesion Kinase in Node-Negative Breast Cancer.

2017

<b><i>Background:</i></b> Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays an important role as a mediator of cell migration, invasion, proliferation and survival. Conflicting results for the prognostic role of FAK in breast cancer (BC) prompted us to determine its impact. <b><i>Methods:</i></b> Patients with node-negative BC entered this retrospective study. FAK expression was determined by immunohistochemistry (n = 335). The prognostic impact of FAK was examined with Cox regression analyses and Kaplan-Meier estimation in the whole cohort as well as in different molecular subtypes. <b><i>Results:</i>&l…

0301 basic medicineOncologymedicine.medical_specialtyUnivariate analysisProportional hazards modelbusiness.industryHazard ratioRetrospective cohort studymedicine.diseaseConfidence intervalFocal adhesion03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicinemedicineImmunohistochemistrySurgeryOriginal ArticlebusinessBreast care (Basel, Switzerland)
researchProduct

Optimization of Lead Placement in the Right Ventricle During Cardiac Resynchronization Therapy. A Simulation Study

2019

[EN] Patients suffering from heart failure and left bundle branch block show electrical ventricular dyssynchrony causing an abnormal blood pumping. Cardiac resynchronization therapy (CRT) is recommended for these patients. Patients with positive therapy response normally present QRS shortening and an increased left ventricle (LV) ejection fraction. However, around one third do not respond favorably. Therefore, optimal location of pacing leads, timing delays between leads and/or choosing related biomarkers is crucial to achieve the best possible degree of ventricular synchrony during CRT application. In this study, computational modeling is used to predict the optimal location and delay of p…

0301 basic medicineOptimizationcomputational modelingmedicine.medical_specialtyQRS durationPhysiologymedicine.medical_treatmentCardiac resynchronization therapycardiac resynchronization therapyheart failureHeart failureLBBB030204 cardiovascular system & hematologylcsh:PhysiologyTECNOLOGIA ELECTRONICA03 medical and health sciencesQRS complex0302 clinical medicinePhysiology (medical)Internal medicinemedicinecardiovascular diseasesOriginal ResearchCardiac resynchronization therapylcsh:QP1-981business.industryComputational modelingmedicine.disease030104 developmental biologymedicine.anatomical_structureVentricleHeart failureCardiologycardiovascular systemLead PlacementbusinessoptimizationFrontiers in Physiology
researchProduct